Proceedings · Session S-921 · filed November 16, 2026
Research Funding & PolicySession paper
FDA Proposes First Drug-to-Supplement Path That Could Reach CBD
FDA's proposed first drug-ingredient exception could formalize NAC supplement sales, potentially open a route for CBD, and start a 60-day Federal Register comment period.
By Priya Raman4 min read798 words
Summary
- The proposal is set for Federal Register publication on November 17, 2026, with a 60-day comment period under docket FDA-2025-N-2699.
- NAC was approved as a prescription drug in 1963 and has been sold as a dietary supplement for more than three decades.
- FDA has exercised temporary enforcement discretion for certain NAC supplements since 2022.
- FDA rejected three citizen petitions seeking a CBD supplement pathway in January 2023; it said the evidence did not establish safety-standard compliance.
- NAC would become the first ingredient included under the proposed dietary-ingredient exception.

By Priya Raman
FDA's proposed rule, set for Federal Register publication on November 17, 2026, would create its first drug-ingredient supplement exception if finalized. Publication would open a 60-day comment period. The proposal centers on N-acetyl-L-cysteine (NAC) and could establish a route for cannabidiol (CBD).
The proposal concerns an ingredient used in both prescription medicines and dietary supplements. FDA says NAC received prescription approval in 1963 and has been sold as a supplement for more than three decades. Because that approval predates the supplement sales, NAC technically falls under the same statutory exclusion as CBD.
The agency has exercised temporary enforcement discretion for certain NAC supplements since 2022. Finalizing the proposal would create a formal regulatory exception for NAC. For research managers, the immediate distinction is legal status. CBD would remain subject to existing restrictions. The proposal does not authorize CBD supplements or signal a decision to pursue that exemption.
What legal mechanism would the proposal create?
Section 201(ff)(3)(B) of the Federal Food, Drug, and Cosmetic Act generally bars ingredients previously approved as drugs from supplement marketing. It also covers ingredients subject to certain clinical investigations. Both groups generally require prior food or supplement sales before the relevant approval or investigation.
The statute also lets FDA grant exceptions through formal rulemaking. In its announcement, the agency said this would be its first use of that authority. The proposed regulation, “Dietary Ingredients Not Excluded from the Dietary Supplement Definition,” would make NAC its first listed ingredient. Its language would leave room to add others later.
FDA said its review of available research led it to determine that NAC could be regulated as a supplement “without undermining prescription drug development.” The finding separates a supplement market from the prescription-drug process. It does not resolve whether the same approach works for other ingredients.
The announcement does not identify the studies in that review, their sample sizes, endpoints, methods, or funding. It therefore supports the regulatory conclusion as an agency finding, not as a reproducible safety dataset.
Sponsors cannot use the announcement alone to assess how much evidence FDA expects for a later ingredient. They would need the docket and its comments to determine that standard.
Could the same route reach CBD?
CBD faces the exclusion because it is the active ingredient in Epidiolex, an FDA-approved prescription medicine used to treat seizures. The restriction applies to CBD itself rather than only to Epidiolex.
If FDA used a comparable exemption, other companies could potentially market CBD dietary supplements, provided they meet applicable safety requirements. That is a projection from the statutory mechanism, not a current approval. The CBD industry has repeatedly called for a federal pathway allowing such sales.
In January 2023, FDA rejected three citizen petitions that asked the agency to use this rulemaking authority for CBD. Regulators concluded then that available evidence did not establish how CBD products could satisfy existing dietary-supplement safety standards. They called on Congress to establish a new framework.
Does the NAC rule change the CBD decision?
No. FDA said the NAC proposal does not reverse the January 2023 rejection. The agency also said it does not intend to pursue a similar exemption for CBD. CBD remains subject to FDA's determination that existing supplement regulations cannot adequately address its safety considerations.
The FDA announcement does not explain, in methodological terms, why its NAC review supports a supplement exception while the CBD record did not. That gap limits any inference that NAC creates an automatic precedent.
A future CBD request would still need to address the safety question the agency found unresolved in 2023.
What changes for R&D and portfolio decisions?
- NAC programs: Manufacturers can use the 60-day docket to examine how a final exception might affect product plans. FDA has not made the exception final.
- CBD programs: Teams should treat the rule as evidence that an FDA route exists, not as market authorization. Any CBD case still faces a separate safety finding and the January 2023 rejection.
- Research planning: The agency cites an unspecified evidence review for NAC. Sponsors seeking a comparable route would need to anticipate the data standard the review does not disclose.
- Prescription portfolios: FDA's finding addresses whether NAC supplement regulation could impede prescription development. It does not establish a general finding for other drug ingredients.
What happens in the next 60 days?
FDA will accept comments for 60 days after publication on November 17, 2026, under docket FDA-2025-N-2699. The announcement gives no final-rule date. It identifies no additional ingredient for immediate inclusion beyond NAC.
If FDA finalizes the exception, NAC will supply the first operational precedent for a drug ingredient in the supplement market, while CBD will still require its own safety determination.
via themarijuanaherald.com (Source)
Filed under
- fda-regulation
- dietary-supplements
- n-acetyl-l-cysteine
- cbd
- drug-to-supplement-pathway
More from Priya Raman
Show full bio
Staff writer covering money, funding and market shifts around research and development at Hypothesis Wire.
281 articles
References
- Jazz Pharmaceuticals Wins Two U.S. Patents Covering CBD-C4 and CBD Derivatives
- FDA Cannabinoid Data-Sharing Pacts: Six Expired, Two Extended to 2031, New York Joins
- Takeda Launches First Orexin Agonist for Narcolepsy Type 1 in US
- Trump's 100% Pharma Tariff Takes Effect; Big Firms Defer Until 2029
- EU Pharmaceutical Overhaul Lands With Procurement Reform and 2028 Deadline